Jim Cramer Praises Johnson & Johnson (JNJ)’s Drugs

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as one of the largest healthcare and pharmaceutical companies globally, recently spinning off its orthopedic business to enhance its growth potential and compete with Eli Lilly [2] Group 1: Company Developments - The spinoff of the orthopedic business is expected to position Johnson & Johnson as a growth stock [2] - The FDA recently approved Caplyta for major depressive disorder, marking a significant advancement in JNJ's drug portfolio for mental health conditions [2] - Johnson & Johnson has been pioneering treatments for suicide prevention with Spravato and is now making strides in addressing major depressive disorder [2] Group 2: Market Position and Future Outlook - Jim Cramer expressed enthusiasm about JNJ's potential to deliver substantive earnings growth through its innovative drug developments [2] - Despite the positive outlook for JNJ, there is a belief that certain AI stocks may offer higher returns with limited downside risk [2]